Navigation Links
Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®
Date:9/19/2011

nformation, please visit http://www.agendia.com.

 



'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LAKE CITY, Jan. 28, 2011 TechniScan (OTC Bulletin ... engaged in the development and commercialization of an automated ... Robinson, Chief Executive Officer, will present at RetailInvestorConferences.com. DATE: ... ESTLINK: , www.retailinvestorconferences.com This will be a live, ...
... BioSciences, Inc. (NasdaqCM: DARA), a biopharmaceutical development company ... through proof of concept in humans for subsequent ... today that Richard Franco, CEO, will present at ... 5:00 PM ESTLINK: , www.retailinvestorconferences.com This will ...
Cached Medicine Technology:TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... government of India.,Clearly positing development against environment, it has asked ... that sits over environmental issues. ,Seeking the vacation ... (FAC), constituted under the Forest Conservation Act, the federal government ... on the ground that it has outlived its utility and ...
... Sir Paul McCartney has offered 20 million pounds to his ... is adamantly demanding 50 million pounds, if reports are ... the couple settled their matter in the range of somewhere ... of estimated 825 million pounds. ,However, their stubbornness ...
... on the Chinese Government to introduce strict regulations to ... summer and winter holiday periods. ,Shang Xiyun ... hearing her eight-year-old daughter declare that she would never ... watching a TV ad for underwear featuring a half-naked ...
... have developed a mathematical model that identifies genes that battle ... ,Researchers conducted a joint study led Dr. Milton Taylor, ... of Evolution of the University of Haifa. ,The ... have had a blood transfusion or who share needles, attacks ...
... found that blood transfusion from donors with undiagnosed cancers ... malignant disease than individuals who receive blood from ... carry out a rigorous battery of tests before the ... diseases are passed between the donor and recipient. Although ...
... the planet, sending automakers back to the drawing board to develop ... ,"There is no doubt that 10 years down ... the planet is going to be higher," said Ghosn, who heads ... ,"The average consumer on earth is going to be much ...
Cached Medicine News:Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 2Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 3Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 4Health News:Blood Transfusions Does Not Increase the Risk of Cancer Transmission 2Health News:Motorists Getting Greyer, Greener, Thriftier: Nissan's Ghosn 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... Conserver., ,Offers an average 5:1 increase in ... the use of a standard cannula. , ... cylinders offers ambulatory oxygen patients a superior alternative ... a 2-year warranty. , ...
Medicine Products: